The first nonionic x-ray contrast agent developed in the U.S. was approved for market by the Food andDrug Administration earlier this month. Optiray, a low-osmolalitynonionic contrast agent manufactured by Mallinckrodt, should reachthe market this
The first nonionic x-ray contrast agent developed in the U.S. was approved for market by the Food andDrug Administration earlier this month. Optiray, a low-osmolalitynonionic contrast agent manufactured by Mallinckrodt, should reachthe market this spring, after the company initiates the new productionprocess. The agent, whose chemical name is ioversol, will be soldinitially for computed tomography, angiography, and urographyapplications, a Mallinckrodt spokesperson said.
Mallinckrodt will market Optiray along with Hexabrix, a low-osmolalityionic contrast agent developed by the French pharmaceutical companyGuerbet. Hexabrix has been on the U.S. market for three years.Omnipaque, a nonionic agent developed by Nycomed of Oslo, Norway,is marketed by Kodak's Winthrop Pharmaceuticals in the U.S.
"The market for contrast media is growing rapidly andan increasing portion of it is shifting to new-generation, low-osmolalityproducts, both nonionic and ionic," said Carl Holman, presidentof Mallinckrodt Medical.
The high cost of these new radiographic contrast agents hasrestrained the market. Mallinckrodt hopes to provide its own nonioniccontrast agent at a lower price than European imports, therebystimulating clinical demand (SCAN 2/17/88). The price of Optiray,however, has not been announced.
Mallinckrodt estimates the current U.S. market for x-ray contrastmedia at $500 million per year and forecasts that sales will reach$1 billion by 1993. U.S. sales constitute about half of the worldwidemarket.
The relatively speedy approval for Optiray was welcomed byMallinckrodt. It had filed for approval with the FDA in June 1987.The most optimistic company projection for the final market go-aheadwas "sometime in 1989."
"Despite increasing demand on limited resources, the FDAprovided a timely review of Optiray, which was a large and complicatednew drug application," said Dr. Edward Aten, vice presidentfor medical affairs.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.